Evaluation of a DTPA prodrug, C2E5 as an orally bioavailable radionuclide decorporation agent

Drug Development Research

Volumn 73, Issue 5, 2012, Pages 243-251

  Sadgrove, Matthew P ^a   Leed, Marina G D ^a   Shapariya, Shraddha ^a   Madhura, Dora Babu ^a   Jay, Michael ^a  

^a University of North Carolina   (United States)

Author keywords

americium; decorporation; DTPA; oral drug delivery; prodrug

Indexed keywords

AMERICIUM 241; CITRIC ACID; NITRATE; PENTETATE CALCIUM; RADIOPHARMACEUTICAL AGENT; RADIOPHARMACEUTICAL AGENT C2E5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; LIVER PROTECTION; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; RADIOACTIVE CONTAMINATION; RADIOISOTOPE DISTRIBUTION; RAT;

EID: 84865064625     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21019     Document Type: Article

References (24)

1. Ansoborlo E, Prat O, Moisy P, Den Auwer C, Guilbaud P, Carriere M, Gouget B, Duffield J, Doizi D, Vercouter T, et al. 2006. Actinide speciation in relation to biological processes. Biochimie 88: 1605-1618. (Pubitemid 44751338)
2. Beaumont K, Webster R, Gardner I, Dack K,. 2003. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab 4: 461-485. (Pubitemid 37540382)
3. Bruenger FW, Kuswik-Rabiega G, Miller SC,. 1992. Decorporation of aged americium deposits by oral administration of lipophilic polyamino carboxylic acids. J Med Chem 35: 112-118.
4. Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW,. 2008. Medical countermeasures against nuclear threats: radionuclide decorporation agents. Radiat Res 170: 540-548.
5. Choppin GR, Thakur P, Mathur JN,. 2006. Complexation thermodynamics and structural aspects of actinide-aminopolycarboxylates. Coord Chem Rev 250: 936-947.
6. Crawley FE, Haines JW,. 1979. The dosimetry of carbon-14 labelled compounds: the metabolism of diethylenetriamine pentaacetic acid (DTPA) in the rat. Int J Nucl Med Biol 6: 9-15. (Pubitemid 9195289)
7. Guilmette RA, Durbin PW,. 2003. Scientific basis for the development of biokinetic models for radionuclide-contaminated wounds. Radiat Prot Dosim 105: 213-218. (Pubitemid 37161222)
8. Guilmette RA, Muggenburg BA,. 1988. Reducing the radiation dose from inhaled americium-241 using continuously administered DTPA therapy. Int J Radiat Biol Relat Stud Phys Chem Med 53: 261-271. (Pubitemid 18060187)
9. Guilmette RA, Durbin PW, Toohey RE, Bertelli L,. 2007. The NCRP wound model: development and application. Radiat Prot Dosim 127: 103-107.
10. Hameln Pharma GmbH. 2009. Package insert: pentetate calcium trisodium injection. Hameln: Hameln Pharma GmbH.
11. Jay M, Mumper RJ,. 2011. Methods and pharmaceutical compositions for decorporation of radioactive compounds. US Patent No. 8,030,358.
12. Markley JF, Rosenthal MW, Lindenbaum A,. 1964. Distribution and removal of monomeric and polymeric plutonium in rats and mice. Int J Radiat Biol Relat Stud Phys Chem Med 8: 271-278.
13. Miale A, Blanchin N, Raynaud P, Quesne B, Giraud JM, Fottorino R, Bérard P, Ansoborlo E, Franck D, Blanchardon E, et al. 2007. MEDOR, a didactic tool to support interpretation of bioassay data after internal contamination by actinides. Radiat Prot Dosim 127: 350-355.
14. National Council on Radiation Protection and Measurements. 2007. Development of a biokinetic model for radionuclide-contaminated wounds and procedures for their assessment, dosimetry, and treatment: recommendations of the National Council on Radiation Protection and Measurements, December 14, 2006. Bethesda, MD: National Council on Radiation Protection and Measurements.
15. National Council on Radiation Protection and Measurements. 2010. Responding to a radiological or nuclear terrorism incident: a guide for decision makers. Bethesda, MD: National Council on Radiation and Protection Measurements.
16. Phan G, Le Gall B, Deverre JR, Fattal E, Benech H,. 2006. Predicting plutonium decorporation efficacy after intravenous administration of DTPA formulations: study of pharmacokinetic-pharmacodynamic relationships in rats. Pharm Res 23: 2030-2035.
17. Roedler HD, Nosske D, Ohlenschlager L, Schieferdecker H, Doerfel H, Renz K,. 1989. Incorporation of 241Am: effectiveness of late DTPA chelation therapy. Radiat Prot Dosim 26: 377-379. (Pubitemid 19123735)
18. Runde WH, Schulz WW,. 2011. Americium. In:, Morss LR, Edelstein NM, Fuger J, editors. The chemistry of the actinide and transactinide elements. New York: Springer, p 1265-1395.
19. Scott KG, Copp DH, Axelrod DJ, Hamilton JG,. 1948. The metabolism of americium in the rat. J Biol Chem 175: 691-703.
20. Silva RJ, Bidoglio G, Robouch PB, Puigdomenech I, Wanner H, Rand MH,. 1995. Chemical thermodynamics of americium. New York: Elsevier.
21. Stradling GN, Gray SA, Moody JC, Pearce MJ, Wilson I, Burgada R, Bailly T, Leroux Y, Raymond KN, Durbin PW,. 1993. Comparative efficacies of 3,4,3-LIHOPO and DTPA for enhancing the excretion of plutonium and americium from the rat after simulated wound contamination as nitrates. Int J Radiat Biol 64: 133-140. (Pubitemid 23248337)
22. Sueda K, Sadgrove MP, Fitzsimmons JM, Jay M,. 2012. Physicochemical characterization of a prodrug of a radionuclide decorporation agent for oral delivery. J Pharm Sci 101: 2844-2853.
23. Volf V,. 1986. Chelation therapy of incorporated plutonium-238 and americium-241: comparison of LICAM(C), DTPA and DFOA in rats, hamsters and mice. Int J Radiat Biol Relat Stud Phys Chem Med 49: 449-462. (Pubitemid 16165413)
24. Wood R, Sharp C, Gourmelon P, Le Guen B, Stradling GN, Taylor DM, Hengé-Napoli M-H,. 2000. Decorporation treatment - medical overview. Radiat Prot Dosim 87: 51-56.